12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

Ipsen, Spirogen deal

Ipsen said in its 3Q12 earnings that in February it sold its remaining 19.31% stake in Spirogen. Ipsen said it received a cash payment and...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >